Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Metformin:

Metformin: New Preparations and Nonglycemic Benefits. Fujita Y et al. Curr Diab Rep. (2017)

Metformin and the gastrointestinal tract. McCreight LJ et al. Diabetologia. (2016)

Metformin - its potential anti-cancer and anti-aging effects. Podhorecka M et al. Postepy Hig Med Dosw (Online). (2017)

Search results

Items: 1 to 20 of 20180

1.

New insights in the AMPK regulation in chicken spermatozoa: Role of direct AMPK activator and relationship between AMPK and PKA pathways.

Nguyen TMD, Grasseau I, Blesbois E.

Theriogenology. 2019 Jul 31;140:1-7. doi: 10.1016/j.theriogenology.2019.07.031. [Epub ahead of print]

PMID:
31419697
2.

Predictors of response to insulin therapy in youth with poorly controlled type 2 diabetes in the TODAY trial.

Bacha F, El Ghormli L, Arslanian S, Zeitler P, Laffel LM, Levitt Katz LE, Gandica R, Chang NT, Sprague JE, Macleish SA; TODAY Study Group.

Pediatr Diabetes. 2019 Aug 16. doi: 10.1111/pedi.12906. [Epub ahead of print]

PMID:
31418516
3.

CDX1 expression induced by CagA-expressing Helicobacter pylori promotes gastric tumorigenesis.

Choi SI, Yoon C, Park MR, Lee D, Kook MC, Lin JX, Kang JH, Ashktorab H, Smoot DT, Yoon SS, Cho SJ.

Mol Cancer Res. 2019 Aug 15. pii: molcanres.0181.2019. doi: 10.1158/1541-7786.MCR-19-0181. [Epub ahead of print]

PMID:
31416838
4.

Association of Metformin Initiation and Risk of Asthma Exacerbation: A Claims-Based Cohort Study.

Wu TD, Keet CA, Fawzy A, Segal JB, Brigham EP, McCormack MC.

Ann Am Thorac Soc. 2019 Aug 15. doi: 10.1513/AnnalsATS.201812-897OC. [Epub ahead of print]

PMID:
31415212
5.

Efficacy and safety of ipragliflozin as add-on to metformin for type 2 diabetes: a meta-analysis of double-blind randomized controlled trials.

Chen W, Li P, Wang G, Chen Y, Wang B, Chen M.

Postgrad Med. 2019 Aug 15. doi: 10.1080/00325481.2019.1655381. [Epub ahead of print]

PMID:
31414934
6.

Editorial: it is not a wide-open field for incretins - collateral benefits favour the use of metformin in advanced non-alcoholic steatohepatitis.

Ratziu V, Pais R.

Aliment Pharmacol Ther. 2019 Sep;50(5):611-612. doi: 10.1111/apt.15414. No abstract available.

7.

Combination of metformin and gefitinib as first-line therapy for non-diabetic advanced NSCLC patients with EGFR mutations: A randomized, double-blind phase 2 trial.

Li L, Jiang L, Wang Y, Zhao Y, Zhang XJ, Wu G, Zhou X, Sun J, Bai J, Ren B, Tian K, Xu Z, Xiao HL, Zhou Q, Han R, Chen H, Wang H, Yang Z, Gao C, Cai S, He Y.

Clin Cancer Res. 2019 Aug 14. pii: clincanres.0437.2019. doi: 10.1158/1078-0432.CCR-19-0437. [Epub ahead of print]

PMID:
31413010
8.

Dynamic risk prediction for diabetes using biomarker change measurements.

Parast L, Mathews M, Friedberg MW.

BMC Med Res Methodol. 2019 Aug 14;19(1):175. doi: 10.1186/s12874-019-0812-y.

9.

Identification and management of prediabetes: results of the Latin America Strategic Prediabetes Meeting.

López-Jaramillo P, Nieto-Martínez RE, Aure-Fariñez G, Mendivil CO, Lahsen RA, Silva-Filho RL, Andreotti LA, Manrique ME, Pasquel-Andrade MA, Rangel I, Vidrio M, Castañeda R, Restrepo M, Pinto ME.

Rev Panam Salud Publica. 2017 Dec 12;41:e172. doi: 10.26633/RPSP.2017.172. eCollection 2017.

PMID:
31410086
10.

National ambulatory care non-insulin antidiabetic medication prescribing trends in the United States from 2009 to 2015.

Kitten AK, Kamath M, Ryan L, Reveles KR.

PLoS One. 2019 Aug 14;14(8):e0221174. doi: 10.1371/journal.pone.0221174. eCollection 2019.

11.

Response of gut microbiota in type 2 diabetes to hypoglycemic agents.

Zhang F, Wang M, Yang J, Xu Q, Liang C, Chen B, Zhang J, Yang Y, Wang H, Shang Y, Wang Y, Mu X, Zhu D, Zhang C, Yao M, Zhang L.

Endocrine. 2019 Aug 13. doi: 10.1007/s12020-019-02041-5. [Epub ahead of print]

PMID:
31410749
12.

What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?

Evans M, Morgan AR, Yousef Z.

Diabetes Ther. 2019 Aug 13. doi: 10.1007/s13300-019-00678-z. [Epub ahead of print] Review.

PMID:
31410711
13.

Adenine nucleotide-mediated regulation of hepatic PTP1B activity in mouse models of type 2 diabetes.

Yang X, Zhao Y, Sun Q, Yang Y, Gao Y, Ge W, Liu J, Xu X, Weng D, Wang S, Zhang J.

Diabetologia. 2019 Aug 13. doi: 10.1007/s00125-019-04971-1. [Epub ahead of print]

PMID:
31410531
14.

Combination of metformin and p38 MAPK inhibitor, SB203580, reduced myocardial ischemia/reperfusion injury in non-obese type 2 diabetic Goto-Kakizaki rats.

Sanit J, Prompunt E, Adulyaritthikul P, Nokkaew N, Mongkolpathumrat P, Kongpol K, Kijtawornrat A, Petchdee S, Barrère-Lemaire S, Kumphune S.

Exp Ther Med. 2019 Sep;18(3):1701-1714. doi: 10.3892/etm.2019.7763. Epub 2019 Jul 10.

15.

The antitumor properties of metformin and phenformin reflect their ability to inhibit the actions of differentiated embryo chondrocyte 1.

Kuo CL, Hsieh Li SM, Liang SY, Liu ST, Huang LC, Wang WM, Yen LC, Huang SM.

Cancer Manag Res. 2019 Jul 15;11:6567-6579. doi: 10.2147/CMAR.S210637. eCollection 2019.

16.

Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma.

Shankaraiah RC, Callegari E, Guerriero P, Rimessi A, Pinton P, Gramantieri L, Silini EM, Sabbioni S, Negrini M.

Oncogene. 2019 Aug 13. doi: 10.1038/s41388-019-0942-z. [Epub ahead of print]

PMID:
31409896
17.

Gut-associated IgA+ immune cells regulate obesity-related insulin resistance.

Luck H, Khan S, Kim JH, Copeland JK, Revelo XS, Tsai S, Chakraborty M, Cheng K, Tao Chan Y, Nøhr MK, Clemente-Casares X, Perry MC, Ghazarian M, Lei H, Lin YH, Coburn B, Okrainec A, Jackson T, Poutanen S, Gaisano H, Allard JP, Guttman DS, Conner ME, Winer S, Winer DA.

Nat Commun. 2019 Aug 13;10(1):3650. doi: 10.1038/s41467-019-11370-y.

19.

Metformin Prolongs Survival in Type 2 Diabetes Lung Cancer Patients With EGFR-TKIs.

Hung MS, Chuang MC, Chen YC, Lee CP, Yang TM, Chen PC, Tsai YH, Yang YH.

Integr Cancer Ther. 2019 Jan-Dec;18:1534735419869491. doi: 10.1177/1534735419869491.

PMID:
31409137
20.

Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer.

Hayashi T, Fujita K, Matsushita M, Nonomura N.

Cancers (Basel). 2019 Aug 12;11(8). pii: E1153. doi: 10.3390/cancers11081153. Review.

Supplemental Content

Loading ...
Support Center